Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson's disease and in neuroleptic treatment

Vision Research
B A HaugW Paulus

Abstract

Following reports on a predominant loss of blue/yellow contrast sensitivity in Parkinson's disease, we revisited the physiological phenomenon of transient tritanopia. Normative data were collected from 33 healthy individuals using different colour and time combinations. Stimuli of 440 nm wavelength (blue) proved optimal, if flashed for 50 msec within the early phase of a 2 sec pause in the 600 nm adaptation light. These conditions were then applied to 15 patients with Parkinson's disease. We found a parallel increase of increment threshold (P < 0.001) and postadaptation thresholds (P < 0.01), with little change in the extent of transient tritanopia. The same tendency at a lower significance level was found in 15 psychiatric patients under chronic treatment with depot neuroleptics.

References

Mar 29, 1977·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·J D Mollon, P G Polden
Apr 13, 1978·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·J E Dowling, B Ehinger
Mar 1, 1990·Trends in Neurosciences·N W DawW J Brunken
Dec 1, 1991·Journal of Structural Biology·M E Bayer
Jan 1, 1990·Epidemiology·K J Rothman
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D G McMahonJ E Dowling
Jan 28, 1985·Brain Research·S Yazulla
Mar 1, 1985·Survey of Ophthalmology·C J Pycock
Jan 1, 1989·The Journal of Comparative Neurology·H Wässle, M H Chun
May 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·E M Lasater, J E Dowling
Jan 31, 1986·Documenta Ophthalmologica. Advances in Ophthalmology·E ZrennerR Adamczyk
Dec 1, 1966·Vision Research·G Westheimer
Feb 4, 1982·Brain Research·S Yazulla, J Kleinschmidt
Aug 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·C Brandon, D M Lam
Dec 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·M Tachibana, A Kaneko
Jan 1, 1983·Vision Research·J J Wisowaty
Mar 1, 1994·Electroencephalography and Clinical Neurophysiology·L BarbatoN Accornero
Jun 1, 1995·Brain : a Journal of Neurology·B A HaugW Paulus
Jan 5, 1995·Nature·V S Ramachandran, S Cobb
Sep 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·B A HaugW Paulus
Oct 1, 1993·Annals of Neurology·W PaulusE Zrenner
Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·T BüttnerH Przuntek
Jan 1, 1993·Fundamental & Clinical Pharmacology·G MassonO Blin
Sep 1, 1989·The European Journal of Neuroscience·H. WässleJ. Röhrenbeck
Jan 1, 1949·Documenta Ophthalmologica. Advances in Ophthalmology·W S STILES

❮ Previous
Next ❯

Citations

Apr 17, 2002·Schizophrenia Research·Sarah M ShuwairiBrian F O'Donnell
May 6, 2004·American Journal of Ophthalmology·Herbert JägleLindsay T Sharpe
Jan 10, 2020·International Journal of Psychiatry in Clinical Practice·Oussama DahdouhDory Hachem
Jun 12, 2021·Psychophysiology·Yuguang ZhaoBart Rypma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here